Published: Sun, September 10, 2017
Health | By Jay Jacobs

FY2019 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Leerink Swann (SRPT)

FY2019 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Leerink Swann (SRPT)

Partnervest Advisory Services Llc sold 23,799 shares as the company's stock declined 6.00% while stock markets rallied.

Fred's, Inc. most recently reported earnings per share (EPS) of -$0.06 for the April 2017 versus $0.04 in the same quarter past year, representing -250% growth. Currently, the stock has a 1 Year Price Target of $67.21.

Metropolitan Life Company New York has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The biotechnology company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts' expectations of $22.52 million.

Exondys 51 is Sarepta's other DMD drug that was approved in September previous year after the U.S. Food and Drug Administration bowed to patient pressure and went against the recommendation of its top scientists and a panel of outside advisers. Leerink Swann has "Outperform" rating and $47 target. If you are viewing this story on another domain, it was copied illegally and republished in violation of US & global copyright & trademark legislation.

Insider Trading Activity for Sarepta Therapeutics, Inc.

A number of other research firms have also recently commented on SRPT. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company's stock worth $156,664,000 after buying an additional 5,175,193 shares during the period.

Traders are more bearish on shares of the company lately if you look at the uptick in short interest. Royal Bank Of Canada reissued a "buy" rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. Credit Suisse Group boosted their target price on the stock of Sarepta Therapeutics from $5.65 to $81.00 and issued the shares an "outperform" recommendation in a analysis report on Thurs. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. In a transaction dated Jul. 20, 2017, the shares were put up for sale at an average price of $41, raking in a sum of $242,638. The total number of shares traded in the last 90-day period is 523,123. RBC Capital Markets maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Friday, December 16 with "Outperform" rating. The high and low revenue estimates for the current quarter are $53.35 Million and $36.45 Million, respectively. Trading was heavy with 12,349K shares changing hands in the last trading session. Next Financial Group, Inc claims 1,200 shares with a value of $40,000,000. Kaye now owns $2,151,311 of the stock according to the SEC filing. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Shamim Ruff sold 12,138 shares of the business's stock in a transaction dated Friday, July 21st. The disclosure for this sale can be found here. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

Several institutional investors and hedge funds have recently modified their holdings of the company. Essex Com Ltd Llc has 0.05% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 11,063 shares. HealthCor Management L.P. grew its stake in Sarepta Therapeutics by 31.1% during the second quarter. PNC Financial Services Group Inc. grew its holdings in Sarepta Therapeutics by 150.1% in the first quarter.

When we see the company's Volatility, it now has a monthly volatility of 4.04% and weekly volatility of 4.54%. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company's stock valued at $154,000 after acquiring an additional 271 shares during the last quarter. Granite Point Capital Management, L.p. now holds 63,220 shares worth $2,131,000. Jennison Associate Ltd Company has invested 0.02% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT).

Like this: